State Street SPDR S&P Biotech ETF (XBI)
| Assets | $7.24B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 62.28M |
| Dividend (ttm) | $0.04 |
| Dividend Yield | 0.03% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Ratio | n/a |
| 1-Year Return | +24.92% |
| Volume | 7,523,693 |
| Open | 123.77 |
| Previous Close | 123.25 |
| Day's Range | 122.69 - 124.18 |
| 52-Week Low | 66.66 |
| 52-Week High | 124.18 |
| Beta | 0.87 |
| Holdings | 135 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
22.02% of assets| Name | Symbol | Weight |
|---|---|---|
| Exact Sciences Corporation | EXAS | 2.78% |
| Revolution Medicines, Inc. | RVMD | 2.64% |
| Avidity Biosciences, Inc. | RNA | 2.33% |
| Natera, Inc. | NTRA | 2.15% |
| BridgeBio Pharma, Inc. | BBIO | 2.13% |
| Insmed Incorporated | INSM | 2.12% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 2.06% |
| Regeneron Pharmaceuticals, Inc. | REGN | 1.96% |
| Ionis Pharmaceuticals, Inc. | IONS | 1.93% |
| Biogen Inc. | BIIB | 1.92% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
| Jun 24, 2024 | $0.11478 | Jun 26, 2024 |
News
3 Potential Mid-Cap Biotech Buyout Targets In 2026
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks ...
Final Trades: FTAI, ETN, COWZ, XBI
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Taiwan Semi, Apple and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech Insiders Are Spending Billions. Trump Favors Less Oversight.
M&A activity is surging. Donald Trump's penchant for deregulation is boosting optimism.
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
XBI: Biotech Funding Condition Recovery Could Be Overdue
US Biotech is lagging other categories in terms of IPO and M&A, but could be overdue for a recovery with capital costs falling. Funding conditions are important for XBI which contains plenty of reflex...
XBI: An Equal Weight ETF On Biotech That Amplifies Its Speculative Component
State Street SPDR S&P Biotech ETF (XBI) has surged nearly 30% YTD, regaining the attention of Wall Street. The outperformance is due to an equal-weight structure, which makes it a high-beta instrument...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one o...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
3 Biotech Stocks I Am Accumulating
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Trade Tracker: Joe Terranova buys more XBI
Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
3 Reasons To Be Optimistic Around Biotech In Q4
The biotech sector has been on the move over the past month, outpacing the returns of the S&P 500 and the NASDAQ over that time. One key reason for this recent surge is that M&A activity is increasing...
Final Trades: SoFi Technologies, Clearway Energy, SPDR S&P Biotech ETF and CrowdStrike
The Investment Committee's top stock picks are in—here's what they're watching now.
As the Fed Pivots, These 3 ETFs Are Positioned to Outperform
The Federal Reserve's inflation battle appears to be ending, and investors who position themselves correctly could capture significant gains. Producer prices unexpectedly dropped in August, while the ...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...